Dirk Arnold - Concepedia

Author

Dirk Arnold

Also Known As

ARNOLD Dirk, Arnold Dirk, Arnold, Dirk, D Arnold, D F Arnold, D. Arnold, D., Arnold, Dirk Arnold, Ramon Salazar, Sebastian Stintzing

185

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

Asklepios Klinik Altona University College London Vall d'Hebron Institute of Oncology Memorial Sloan Kettering Cancer Center Assistance Publique – Hôpitaux de Paris

About

Dirk Arnold is an author at Asklepios Klinik Altona specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	18	3.6K
2	Health Sciences	6	6	1.7K
3	Hepatology	4	4	1.1K
4	Gastroenterology	1	1	1.2K
5	Immunology	1	1	14

Dirk Arnold

Publications

7.6K

Citations

H-Index

Page 1

	Year	Citations
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer Talia Golan, Pascal Hammel, Michele Reni, New England Journal of Medicine	2019	2.1K
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Guillem Argilés, Josep Tabernero, Roberto Labianca, Annals of Oncology Gastrointestinal OncologyColorectal SurgeryMedicineCancer ManagementGastroenterology	2020	1.2K
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Arndt Vogel, Andrés Cervantes, Ian Chau, Annals of Oncology HepatologyMedicineHistopathologyLiver DiseaseLiver Cancer	2018	1K
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, Annals of Oncology	2017	576
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Sun Young Rha, Do‐Youn Oh, Patricio Yañez, The Lancet Oncology Chemotherapy Versus PlaceboGastrointestinal OncologyMedicineClinical TrialsImmune Checkpoint Inhibitor	2023	521
Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020 Jeanin E. van Hooft, Joyce Veld, Dirk Arnold, Endoscopy	2020	330
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen, Annals of Oncology	2019	232
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer Hedy L. Kindler, Pascal Hammel, Michele Reni, Journal of Clinical Oncology	2022	200
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy Axel Grothey, Josep Tabernero, Dirk Arnold, Annals of Oncology MedicineCancer ManagementPathologyColorectal CancerBiomarker-driven Maintenance Treatment	2018	103

Page 1